Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFFITOPE PD03A in Early Parkinson's Disease
NCT02267434Phase 1Completed
- Sponsor
- AFFiRiS
- Start
- Dec 2014
- Primary completion
- Aug 2016
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of AFFITOPE PD03A in Parkinson's disease (PD) (3 arms), sponsored by AFFiRiS. Primary endpoints: Number of patients who withdraw due to Adverse Events at 12 months, Occurrence of Adverse Events and Serious Adverse Events at 12 months and 4 more. Started Dec 2014; status: completed.
02
Drugs
AFFITOPE PD03A
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02267434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02267434.